Cargando…

Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474)

Proteasome inhibitors have been proven to be effective anticancer compounds in many tumor models, including glioblastoma multiforme (GBM). In this study, we found that the proteasome inhibitor Velcade (PS-341/bortezomib) caused GBM cell death while simultaneously activating the PI3K/Akt pathway. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	LIN, LEHANG, GAUT, DARIA, HU, KAISHUN, YAN, HAIYAN, YIN, DONG, KOEFFLER, H. PHILLIP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898871/ https://www.ncbi.nlm.nih.gov/pubmed/24297065 http://dx.doi.org/10.3892/ijo.2013.2205

Ejemplares similares

In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells
por: Zhao, Wennan, et al.
Publicado: (2013)

Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MS
por: Akashi, Tetsuyuki, et al.
Publicado: (2009)

ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair
por: Jiao, Wenhui, et al.
Publicado: (2022)

Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines
por: Namatame, Nachi, et al.
Publicado: (2018)

Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474
por: Isoyama, Sho, et al.
Publicado: (2015)

ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells
por: Wang, Yaochen, et al.
Publicado: (2016)

Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice
por: Toyama, Shoko, et al.
Publicado: (2010)

The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina
por: Chen, Fang-Ting, et al.
Publicado: (2013)

Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells
por: Bertazza, Loris, et al.
Publicado: (2015)

In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells
por: Zhou, Qianxiang, et al.
Publicado: (2016)

Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells
por: Zhou, Qianxiang, et al.
Publicado: (2017)

Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury
por: Wang, Po, et al.
Publicado: (2016)

The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress
por: Jiang, Jinqiong, et al.
Publicado: (2021)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Proteasome inhibitors in glioblastoma
por: Huang, Wen-Juan, et al.
Publicado: (2017)

Proteasome inhibitors in glioblastoma
por: Huang, Wen-Juan, et al.
Publicado: (2017)

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme
por: Lubanska, Dorota, et al.
Publicado: (2017)

In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme
por: Kirubakaran, Palani, et al.
Publicado: (2011)

Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2018)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
por: Xavier, Mary-Ann, et al.
Publicado: (2021)

TBK1 Inhibitor Exerts Antiproliferative Effect on Glioblastoma Multiforme Cells
por: Scuderi, Sarah A., et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

A case of bortezomib (Velcade)–induced Stevens-Johnson syndrome confirmed by patch test
por: Choi, Gil-Soon, et al.
Publicado: (2021)

Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors
por: Nicholas, Sarah, et al.
Publicado: (2013)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Retraction Note: Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2021)

Design and Computational Analysis of an MMP9 Inhibitor in Hypoxia-Induced Glioblastoma Multiforme
por: Kumari, Smita, et al.
Publicado: (2023)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer
por: Yan, Haiyan, et al.
Publicado: (2016)

Group-assisted purification (GAP) chemistry for the synthesis of Velcade via asymmetric borylation of N-phosphinylimines
por: Xie, Jian-bo, et al.
Publicado: (2014)

Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
por: Costa, Barbara, et al.
Publicado: (2013)

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy
por: Roche, Kyle C., et al.
Publicado: (2022)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Incidentalomas to glioblastoma multiforme
por: Sachdev, Bobby, et al.
Publicado: (2014)

Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo
por: Manton, Christa A., et al.
Publicado: (2016)

Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
Publicado: (2020)

Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells
por: Abdi, J, et al.
Publicado: (2013)

ProNGF Expression and Targeting in Glioblastoma Multiforme
por: Marsland, Mark, et al.
Publicado: (2023)

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
por: Zhao, Hua-fu, et al.
Publicado: (2017)

Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming
por: Bernstock, Joshua D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cb0epjl4k10pcgiriuigsm5uv3